



Our STN: BL125111/904

SUPPLEMENT APPROVAL

Sanofi Pasteur Limited
Attention: Michael Stirr
1755 Steele Avenue
Toronto, Ontario
Canada M2R 3T4

January 9, 2023

Dear Mr. Stirr:

We have approved your request received December 10, 2021, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (ADACEL), manufactured at your Toronto, Canada facility, to include immunization during the third trimester of pregnancy to prevent pertussis in infants younger than 2 months of age.

The review of this supplement was associated with the following National Clinical Trial (NCT) number(s): NCT00258882, NCT05040802

LABELING

Under 21 CFR 201.57(c)(18), patient labeling must be referenced in section 17 PATIENT COUNSELING INFORMATION. Patient labeling must be available and may either be reprinted immediately following the full prescribing information of the package insert or accompany the prescription product labeling.

We hereby approve the draft content of labeling: Package Insert submitted under amendment 22, dated January 9, 2023, Patient Package Insert submitted under amendment 19, dated December 23, 2022, and the draft carton and container labels submitted with the application under amendment 0, dated December 10, 2021.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the Package Insert, and Patient Package Insert, submitted on January 9, 2023 and December 23, 2022, respectively. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS

Please electronically submit final printed carton and container labels identical to the carton and container labels submitted on December 10, 2021 , according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-certain-human-pharmaceutical-product-applications>.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125111 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes this change.

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and

effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages birth to age less than 10 years because the product fails to represent a meaningful therapeutic benefit over existing therapies and is unlikely to be used in a substantial number of children in this age group for this indication. This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional pediatric studies are needed at this time.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We acknowledge your written commitments as described in your correspondence of January 9, 2023, as outlined below:

To conduct an observational safety cohort study using electronic health care data with linkage to offspring and access to clinical records in the US, to evaluate pregnancy outcomes in individuals exposed to Adacel. The population will be comprised of eligible pregnant individuals exposed to Adacel as of the 1st day of the 27th week of gestation or later and an active comparator of pregnant individuals not vaccinated with any Tdap vaccines during pregnancy. The study will include pre-defined pregnancy, birth and neonatal outcomes.

Final Protocol Submission: June 30, 2023

Study/Trial Completion Date: December 31, 2025

Final Report Submission: December 31, 2026

Please submit the clinical protocol to your IND 9226, and a cross-reference letter to BLA STN BL 125111 explaining that this protocol was submitted to the IND.

If the information in the final study report supports a change in the labeling, the final study report must be submitted as a supplement. Please use the following designators to prominently label all submissions, including supplements, relating to these postmarketing study commitments as appropriate:

- **Postmarketing Commitment – Correspondence Status Update**
- **Postmarketing Commitment – Final Study Report**
- **Supplement contains Postmarketing Commitment Final Study Report**

For each postmarketing study subject to the reporting requirements of 21 CFR 601.70, you must describe the status in an annual report on postmarketing studies for this product. Label your annual report as an **Annual Status Report of Postmarketing Requirements/Commitments** and submit it to the FDA each year within 60 calendar days of the anniversary date of the approval of BLA STN BL 125111 until all

requirements and commitments subject to the reporting requirements of section 506B of the Federal Food, Drug, and Cosmetic Act (FDCA) are fulfilled or released. The status report for each study should include:

- the sequential number for each study as shown in this letter;
- information to identify and describe the postmarketing commitment;
- the original schedule for the commitment;
- the status of the commitment (i.e., pending, ongoing, delayed, terminated, or submitted); and,
- an explanation of the status including, for clinical studies, the patient accrual rate (i.e., number enrolled to date and the total planned enrollment).

As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our website at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm>.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

For Rebecca Reindel, M.D.
Acting Deputy Director - Clinical
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research